Introduction {#s1}
============

SLC1A5 (ASCT2) catalyzes an obligatory Na^+^-dependent antiport in which Na^+^ together with an extracellular neutral amino acid are exchanged with an intracellular neutral amino acid ([@bib20]; [@bib42]). Among the solute carrier family 1 (SLC1) sub-family, it is the only one that is competent to transport glutamine, and it serves as the primary transporter of glutamine in cancer cells ([@bib11]). Inhibition of SLC1A5 glutamine transport by small molecules and shRNA-mediated SLC1A5 knockdown have been shown to decrease endometrial cancer cell growth ([@bib24]). Similarly, SLC1A5 inhibition and knockdown suppressed mTORC1 signaling and induced rapid cell death in breast cancer cells ([@bib43]). In addition, SLC1A5 ^-/-^ mice are deficient in T cell receptor-mediated activation of the metabolic kinase mTORC1 and as a result exhibit improved clinical scores in experimental autoimmune animal models of multiple sclerosis and colitis ([@bib25]).

The structure and function of SLC1 transporters have been studied using bacterial aspartate transporter homologues Glt~PH~ from *Pyrococcus horikoshii* ([@bib46]; [@bib5]; [@bib30]; [@bib15]; [@bib2]; [@bib19]), Glt~TK~ from *Thermococcus kodakarensis* ([@bib18]; [@bib17]), human glutamate transporter SLC1A3 ([@bib6]) and glutamine transporter SLC1A5 ([@bib13]; [@bib14]). All these transporters form a trimer of independently functioning protomers that uses an elevator mechanism to carry amino acids across membranes ([@bib2]; [@bib10]). Each protomer has a scaffold domain and a movable transport domain which slides and carries the solute. Glt~PH~ structures have been reported in both the outward- and the inward-facing states ([@bib5]; [@bib30]; [@bib2]; [@bib44]; [@bib45]). Crystal structures of unbound and substrate-bound Glt~TK~ have also been reported in the outward-facing conformation. The crystal structures of SLC1A3 were determined with competitive and allosteric inhibitors in the outward-facing conformation ([@bib6]). Crystallographic studies of SLC1A3 required mutation of nearly 25% of its primary sequence suggesting the inherent technical challenges with this gene family ([@bib6]). Recently, the cryo-EM structures of SLC1A5 in complex with glutamine or inhibitor were reported in the inward-facing state ([@bib13]; [@bib14]). To gain insights into structural features that permit substrate recognition in an outward-facing state, using an antibody fragment as a fiducial marker we have solved the cryo-EM structures of the unliganded transporter and its complex with glutamine at 3.5 and 3.8 Å resolution, respectively.

Results {#s2}
=======

Our full-length SLC1A5 construct showed high expression and stability. ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The presence of affinity tags used for purification did not affect the sodium-dependent glutamine uptake when HAP1 SLC1A5 knock-out cells were transiently transfected with full-length SLC1A5 but the observed transport activity was low, compared to the background. To assist structural determination, we generated its complex with a commercially available cKM4012 Fab fragment. It is reported that KM4012 antibody isolated through a cell-based screen inhibited glutamine-dependent cancer cell growth ([@bib41]). The purpose of the Fab was to serve as a fiducial marker for particle alignment. Negative-stain electron microscopy revealed that one molecule of Fab was bound to each protomer of a SLC1A5 homotrimer ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The three-fold symmetry was broken due to the dynamic nature of each Fab and protomer. Single-particle electron cryo-microscopy (cryo-EM) analysis without imposing any symmetry restraint resulted in a facile three-dimensional reconstruction at an overall resolution of 3.5 Å (Fourier shell correlation (FSC) = 0.143 criterion; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The highly flexible Fab fragments were masked out to maximize the structural quality of SLC1A5 ([Figure 1---figure supplements 2](#fig1s2){ref-type="fig"},[3](#fig1s3){ref-type="fig"}). The quality of the EM density map was sufficient to allow model building for residues 43--488 ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). The limited resolution on the Fab region prevents a detailed and accurate analysis of the protein-fab interface.
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###### Data collection, reconstruction, and model refinement statistics

  ------------------------------------------------------------------------------
                                  SLC1A5_cKM4012\       SLC1A5_cKM4012_L\_Gln\
                                  EMD-9187, PDB: 6MP6   EMD-9188, PDB: 6MPB
  ------------------------------- --------------------- ------------------------
  **Data collection**                                   

  Microscope                      Titan Krios           Titan Krios

  Voltage (keV)                   300                   300

  Nominal magnification           22,500 x              22,500 x

  Exposure navigation             Stage Position        Stage Position

  Electron exposure (e /Å^2^)     42                    42

  Dose rate (e/pixel/sec)         5                     5

  Detector                        K2 Summit             K2 Summit

  Pixel size (Å)^\*^              0.543                 0.543

  Defocus range (µm)              1.2 to 2.5            1.2 to 2.5

  Micrographs Used                3804                  5228

  Final Refined particles (no.)   165,067               253,220

  **Reconstruction**                                    

  Symmetry imposed                C1                    C1

  Resolution (global)                                   

  FSC 0.143                       3.50 Å                3.83 Å

  Applied B-factor (Å^2^)         −15                   −15

  **Refinement**                                        

  Protein residues                1341\                 1344\
                                  (SLC1A5)              (SLC1A5_L\_Gln)

  Map Correlation Coefficient     0.815                 0.785

  R.m.s deviations                                      

  Bond lengths (Å)                0.006                 0.005

  Bond angles (°)                 1.085                 1.062

  Ramachandran                                          

  Outliers                        0.00%                 0.00%

  Allowed                         7.88%                 8.93%

  Favored                         92.12%                91.07%

  Poor rotamers (%)               0.00%                 0.00%

  MolProbity score                1.62                  1.67

  EMRinger score                  2.59                  1.99

  Clashscore (all atoms)          3.44                  3.67
  ------------------------------------------------------------------------------

^\*^Calibrated pixel size at the detector.

The structure of SLC1A5 shows a homotrimer with an overall Glt~PH~-like fold in an outward-facing conformation, Each SLC1A5 protomer contains two domains, a transport domain and a scaffold domain connected by the extracellular loop region 2 (ECL2a and ECL2b) ([Figure 1a-c](#fig1){ref-type="fig"}, [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). The individual transport domain containing transmembrane helices TM3, TM6-TM8 and helical loops 1--2 (HP1-HP2) interacts exclusively with the scaffold domain from its own protomer. The scaffold domain including TM1-TM2 and TM4-TM5 is involved in inter-protomer interactions and forms a compact core. The ECL2 connects TM3 to TM5 via TM4 and bridges the two domains. ECL2a spans about 55 Å across a quarter of the transport domain, sequentially interacting with ECL3, TM8, TM7a, and HP2b on extracellular surface.

![Cryo-EM structure of human SLC1A5.\
(**a**) A density map of SLC1A5 homotrimer viewed from the side of the membrane (left) and the extracellular face (right) highlighting the scaffold domain (green), transport domain (navy), ECL2 (red) and N-acetyl-D-glucosamine (NAG, in orange). The density assigned to CHS is colored in magenta. (**b**) Micelle/membrane and trimerization interfaces are highlighted in gray and wheat, respectively. Interactions between transport and scaffold domains are illustrated with lines. (**c**) A schematic representation of the domains present in human SLC1A5. The N-linked glycosylation sites are indicated by orange circle. Dashed lines represent residues disordered in the structure.](elife-48120-fig1){#fig1}

Superposition with the inward-facing state demonstrates that the scaffold domain remains relatively rigid, while the transport domain moves toward the cytoplasm and the substrate binding site shifts by 19 Å toward the cytoplasmic face ([Figure 2a-b](#fig2){ref-type="fig"}) ([@bib13]). The ECL3 possessing one α-helix with \~1.5 turns connects the TM6 to the TM5 of the scaffold domain in the outward-facing state ([Figure 2a](#fig2){ref-type="fig"}). In the inward-facing state (PDB: 6GCT), this 1.5 turn α-helix in ECL3 merges into TM6 which extends the length of TM6 by about 9.5 Å ([Figure 2a,c](#fig2){ref-type="fig"}) ([@bib13]). As a result, the shortened ECL3 further pulls the N-terminus of TM6 close to the TM5 causing the movement of TM6 toward the cytoplasm with \~40° tilt compared to the outward-facing state ([Figure 2a](#fig2){ref-type="fig"}). Simultaneously, to compensate the movement of the transport domain and the conformational changes of TM6, the N-terminus of TM3 unwinds by approximately 1.5 turns and extends the TM2-3 loop in the cytoplasmic space ([Figure 2b--c](#fig2){ref-type="fig"}). The extension of TM2-3 loop increases the distance between TM2 and TM3, resulting in a \~ 20° tilt compared to the outward-facing state ([Figure 2b](#fig2){ref-type="fig"}). The structurally symmetrical TM3 and TM6 serve as a platform which holds the core region of the transport domain ([Figure 2c](#fig2){ref-type="fig"}). During the transition between outward- and inward-facing states, the changes in lengths of the TM3, TM2-3 loop, TM6 and ECL3 regions trigger the adjustment in the platform plane relative to the membrane plane, resulting in the movement of the transport domain coupled with a \~ 30° rotation ([Figure 2a-c](#fig2){ref-type="fig"}) ([@bib13]). Notably, the well-defined ECL2a undergoes a large conformational rearrangement, swinging out by \~35° relative to the transport domain when compared with an inward-facing state of a cross-linked Glt~PH~ structure ([Figure 2d](#fig2){ref-type="fig"}) ([@bib30]). In the outward-facing state, the ECL2a encompasses one side of the transport domain and is positioned to expose both the ECL4 and ECL5. However, in the inward-facing state, the ECL2a forms a sharp turn and sits on top of the transport domain covering a narrow groove formed by the ECL4 and ECL5 to accommodate rigid body movement of the transport domain ([@bib30]; [@bib44]; [@bib45]; [@bib31]).

![Structural comparison between outward- and inward-facing states of SLC1A5.\
(**a and b**) Structure of the SLC1A5 monomer viewed from the side of the membrane highlighting TM6 and TM3, respectively. Transport domains are represented as molecular surfaces and colored in navy. Scaffold domains are in green. TM6 and TM3 are colored in orange in the outward-facing state (left) and pink in the inward-facing state (middle, PDB: 6GCT). Overlay of scaffold domains of inward- and outward-facing states highlighting TM3 and TM6 (right). The glutamine substrate is shown as a red ball. (**c**) Superposition of the transport domains of SLC1A5 in the outward- and inward-facing (PDB: 6GCT) states (left). The conformational changes of TM6 (middle) and TM3 (right) between the outward-facing and inward-facing states are highlighted. (**d**) Transport domains of SLC1A5 in an outward-facing state (left) and a cross-linked Glt~PH~ in inward-facing state (middle, PDB:3KBC) viewed from the extracellular face. The SLC1A5 transport domain in the outward-facing conformation serving as the reference is shown in molecular surface. The conformational changes of ECL2a between the outward- (in red) and inward-facing (in cyan) states are highlighted (right).](elife-48120-fig2){#fig2}

To understand the basis for substrate recognition by SLC1A5, we solved the cryo-EM structure of SLC1A5 in the presence of the substrate, L-Gln at 3.8 Å resolution ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). The density was sufficient to dock the L-Gln molecule ([Figure 3a](#fig3){ref-type="fig"}). The Gln binding pocket is formed by two oppositely oriented reentrant loops (HP1 and HP2), TM7 and TM8 of the transport domain ([Figure 3a--b](#fig3){ref-type="fig"}). The HP2 loop in the unliganded structure is in an open conformation providing a direct access to the binding site. Upon Gln binding, HP2 loop acts as a gatekeeper and comes close to the serine-rich HP1 loop to shield the substrate from the extracellular surface ([Figure 3a](#fig3){ref-type="fig"}). Furthermore, the substrate binding interaction is maintained between the two states of SLC1A5 ([Figure 3c](#fig3){ref-type="fig"}) ([@bib13]). Both α-amino and α-carboxylate groups of the substrate appear to be anchored by the carbonyl backbone of Ser351, the amide backbone and the sidechain of Ser353 in the HP1 loop and can be further stabilized by sidechains of Asp464 and Asn471 in TM8 ([Figure 3b](#fig3){ref-type="fig"}). Importantly, the Nε2 of the substrate, L-Gln, is within hydrogen bond distance to the sidechain of Asp464 in TM8. A smaller substrate, L-Asn, could fit into the binding site to satisfy the interaction with Asp464, consistent with the comparable K~m~ values of human SLC1A5 for L-Asn and L-Gln determined in proteoliposomes ([@bib34]). The position of L-Gln in our SLC1A5 structure is similar to that of the L-Asp in the SLC1A3 crystal structure, suggesting a conserved-ligand binding pocket among SLC1 family members ([Figure 3d](#fig3){ref-type="fig"}) ([@bib46]; [@bib6]).

![The substrate, L-glutamine-bound SLC1A5 structure.\
(**a**) Conformational change for the HP2 upon binding of L-glutamine in the outward-facing state of SLC1A5. The unliganded structure is shown in gray and the L-glutamine-bound structure is in navy. EM density over the ligand is shown as a blue mesh. (**b** and **c**) Zoomed in views of the substrate binding sites of the outward-facing and inward-facing states (PDB:6GCT) of SLC1A5, respectively. (**d**) Interaction of L-Asp in the outward-facing state of SLC1A3 (PDB code: 5LLU). Critical side chains are labeled (stick representation) with hydrogen bonds (red dashed lines). Molecular surface in the substrate binding sites are in pink.](elife-48120-fig3){#fig3}

Cys467, a unique residue among the SLC1 family, is at a suitable distance to donate its proton to the carbonyl group of the Gln substrate ([Figure 3b](#fig3){ref-type="fig"}, [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}) and could thus contribute to substrate selectivity. Mutation of Cys467 to Ala in SLC1A5 showed significant increase in K~m~ for Gln ([@bib35]). The corresponding residue in all glutamate transporters of the SLC1 family is a conserved bulkier Arg residue ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). In SLC1A3, the Arg residue with its guanidinium group forms a hydrogen bond with the carboxylate group of the substrate Asp, and a favorable cation-π interaction with a Tyr residue ([Figure 3d](#fig3){ref-type="fig"}). As a result of the smaller amino acid at this location, SLC1A5 has an additional side cavity involving Phe393, Val436, Ala433, Val463 and Asp464, whereas no such cavity is present in SLC1A3 ([Figure 3b,d](#fig3){ref-type="fig"}). Besides the difference in the pocket size and shape, Arg in place of the Cys will lead to steric clashes with the Gln substrate in SLC1A5. The critical role of the Cys467 in SLC1A5 for substrate specificity was further supported by an equivalent mutation of threonine in SLC1A4 (Thr459) to a cysteine, resulting in alteration to L-Gln binding ([@bib38]) and inhibition by Cys modifying reagents in proteoliposome assays ([@bib29]). Since the structure of SLC1A4 is unknown, we attempted to generate a model for SLC1A4 by replacing Cys with a threonine. Unfortunately, none of the three rotamers available for threonine can be satisfactorily accommodated because of steric clashes with backbone carbonyl atoms. This suggests that SLC1A4 must have a slightly different local conformation around the substrate binding site. Regardless of the local conformation that SLC1A4 adopts in this region, the side chain hydroxyl group of Thr459 (analogous to Cys467 in SLC1A5) is unlikely to form a productive hydrogen bonding interaction with the glutamine substrate and this could explain why the former transports only fewer amino acids. Ala390, a conserved residue in neutral amino acid transporters, SLC1A4 and SLC1A5, does not form any contact with the Gln substrate and could tolerate small neutral amino acid substrates ([Figure 3b](#fig3){ref-type="fig"}, [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). In contrast, the structurally equivalent residue Thr in SLC1A3 forms a hydrogen bond with the carboxylate group of the substrate.

Stretches of residual EM densities were observed in a hydrophobic crevice near the domain interface in the presence or absence of glutamine ([Figure 1a](#fig1){ref-type="fig"}). Based on the shape of the density and the presence of cholesteryl hemisuccinate (CHS) during purification, we assigned this density to CHS. Using an unbiased lipidomics approach, CHS was detected as a major component in the sample used for cryo-EM. The identity of CHS was further confirmed by mass spectrometry using commercially available CHS as a reference ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

The cryo-EM density supports a specific binding site for CHS in the outward-facing SLC1A5 conformation. Electron density suggests that CHS binds inside a hydrophobic pocket formed by TM3, TM4a, TM4c and TM7 from one protomer, as well as TM5 from the adjacent protomer ([Figure 3---figure supplements 2](#fig3s2){ref-type="fig"},[3](#fig3s3){ref-type="fig"}). The putative lipid density was also observed in the inward-facing state of SLC1A5, located in a hydrophobic pocket formed by TM3, TM4a, TM4c, and HP2a from one protomer, and TM5 from the adjacent protomer ([@bib13]). Docking a CHS molecule in this putative density shows that the corresponding location is similar to that of the outward-facing state despite different pocket shape between two conformational states ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Remarkably, the specific CHS-binding site in SLC1A5 overlaps with the UCPH~101~ allosteric binding site reported in SLC1A3 structure ([@bib6]) ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). The highly lipophilic UCPH~101~ binds in the outward-facing conformation and blocks the movement of the transport domain relative to the scaffold domain. Additional putative lipid density was reported previously in the inward-facing state of SLC1A5, located between the transport and scaffold domains within the same protomer ([@bib13]). The corresponding density was not observed in the outward-facing state of SLC1A5 due to differences in the local environment between the transport and scaffold domains.

Discussion {#s3}
==========

Human SLC1A5 is the first eukaryotic sodium-dependent neutral amino acid transporter for which both the inward- and outward-facing conformational states have been mapped by cryo-EM. Our cryo-EM structures of unbound and substrate-bound SLC1A5 revealed that HP2 is the extracellular gate that controls entry of the substrate ([@bib5]; [@bib6]). As a gatekeeper, HP2 in the closed conformation is near the serine-rich HP1, shielding the substrate from the extracellular surface ([Figure 3a](#fig3){ref-type="fig"}). The structure of the unliganded form of SLC1A5 provides an example for the HP2 loop in an open conformation and serves as a useful starting model for designing competitive inhibitors such as TBOA ([@bib5]; [@bib7]). The opening of the HP2 loop increases the accessible surface area, exposing a previously unidentified cryptic pocket which could accommodate a large inhibitor that could specifically target the open conformation. In contrast, the closed conformation of HP2 has a small binding site, limiting the size of the inhibitors ([@bib8]; [@bib40]).

The availability of the three-dimensional structure of SLC1A5 in its outward-facing conformation open several paths forward for the development of drugs. The structure could be used for example identification of chemical leads by virtual screening methods. Secondly, generating additional structures with lead molecules based on substrate-analogs could provide a strong structure-based drug design platform for medicinal chemistry optimization of compound potencies. One important aspect of drug discovery is the need to engineer selectivity of lead compounds for the specific target in a given family. This is especially true for modulators of SLC1A5 where dialing out off-target activities against other closely-related sub-family members is highly desirable. Historically, this has been an area of strength for structure-based design. Structures have also been incredibly useful for optimization of ADME properties of compounds which is a critical element in the overall drug discovery process. Lastly, we believe the most relevant conformation to target for SLC1A5 inhibitors is the outward-facing conformation that we have described in our current work as that might be readily accessible for ligands from extracellular space.

The human SLC1A5 represents a distinct SLC1 subfamily identifiable in part by the Cys and Ala residues for substrate specificity and the unique conformation of the two ECL2a and ECL2b loops allowing for structural flexibility at TM4b for the key trimer interaction. Furthermore, ECL2a encircles the transport domain in the outward-facing state, covering a large part of the interaction surface for the inward facing state. In the inward-facing state the ECL2a is repositioned, exposing the interaction surface for the scaffold domain ([Figure 4](#fig4){ref-type="fig"}) ([@bib13]).

![Schematic representation of conformational changes in SLC1A5 during substrate transport.\
(**a**) In the outward-facing state (top), the Zone two from the transport domain interacts with the scaffold domain, with the Zone one partially occupied by the ECL2a. Two different poses of the ECL2a were observed (shown in red and dark gray lines): one is situated at the side of the transport domain (red line); the other is crossing over the crests of ECL4 and ECL5 (dark gray line). In the inward-facing state (bottom), the ECL2a has to be repositioned, releasing the Zone one to interact with the scaffold domain. Residues from Zone one and Zone two are highlighted ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). (**b**) The inherent plasticity around the TM2-3 loop, ECL3, TM3, and TM6 regions (highlighted in dash lines) allows the transitions between the outward-facing (top) and inward-facing states (bottom). The relative position of transport domain in the outward-facing state is highlighted in dash (bottom panel in b). The regions of SLC1A5 are colored based on the [Figure 1a](#fig1){ref-type="fig"}. The light gray line depicts membrane boundary.](elife-48120-fig4){#fig4}

The existence of a potential allosteric binding pocket observed in the outward- and inward-facing SLC1A5 structures could facilitate the design of selective inhibitors that can bind to a site that is remote from the conserved substrate-binding site. Such allosteric druggable pockets at the lipid-exposed surface near the intracellular portions of membrane proteins have recently been structurally elucidated in several proteins and this raises new opportunities for drug design ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). We believe that these findings provide new and exciting structural insights and opportunities for antagonizing glutamine metabolism at the transporter level. Our structures of human SLC1A5, in both unbound and substrate-bound forms, represent the first high resolution cryo-EM structures of SLC1 family captured in the outward-facing state. These structures are an early example of the value that cryo-EM may bring to structure-based drug design.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\                      Designation                           Source or\             Identifiers                                                   Additional\
  or resource                                                                        reference                                                                            information
  -------------------------------------------- ------------------------------------- ---------------------- ------------------------------------------------------------- ---------------
  Antibody                                     Mouse monoclonal Anti-SLC1A5          Creative Biolabs Inc   TAB-1010CLV                                                   1 ml, 1 mg/ml

  Strain, strain background (*Homo sapiens*)   HEK293S GnTI^-^ cells                 ATCC                   CRL-3022\                                                     
                                                                                                            RRID: [CVCL_A785](https://scicrunch.org/resolver/CVCL_A785)   

  Recombinant DNA reagent                      pcDNA3.1^+^                           Life Technologies      V79020                                                        

  Chemical compound, drug                      Opti-MEM reduced serum media          Life Technologies      31985062                                                      

  Strain, strain background (*Homo sapiens*)   HAP1 SLC1A5 knock out cells           Horizon Discovery      HZGHC005452c002                                               

  Chemical compound, drug                      Iscove's modified Dulbecco's medium   Gibco                  12440                                                         

  Chemical compound, drug                      Cell dissociation buffer              Gibco                  13151                                                         

  Chemical compound, drug                      Fetal bovine serum                    Gibco                  16000044                                                      

  Software, algorithm                          MotionCorr2 1.1.0                     [@bib49]               <http://msg.ucsf.edu/em/software/motioncor2.html>             

  Software, algorithm                          Relion v 2.0                          [@bib21]               <https://www2.mrc-lmb.cam.ac.uk/relion/>                      

  Software, algorithm                          Phenix 1.14                           [@bib1]                <http://phenix-online.org/>                                   

  Software, algorithm                          Coot 0.8.9.1                          [@bib9]                <https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>       

  Software, algorithm                          Pymol 2.0                             Schrodinger LLC        <https://pymol.org/2/>                                        

  Software, algorithm                          Chimera 1.12                          [@bib28]               <https://www.cgl.ucsf.edu/chimera/>                           

  Software, algorithm                          Gctf                                  [@bib47]               <https://www.mrc-lmb.cam.ac.uk/kzhang/>                       

  Software, algorithm                          cisTem                                [@bib16]               <https://cistem.org/>                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein expression {#s4-1}
------------------

The gene encoding SLC1A5 was cloned into pcDNA3.1^+^ (Life Technologies) where it was fused to a C-terminal His10-Flag affinity double tag separated by TEV protease cleavage site. The protein was expressed in HEK293S GnTI^-^ cells (ATCC CRL-3022, RRID: [CVCL_A785](https://scicrunch.org/resolver/CVCL_A785)) grown in Expi293 Expression Media (Life Technologies) to densities 2.5 × 10^6^ cells ml^−1^. Cells were transiently transfected in Opti-MEM reduced serum media (Life Technologies) using ExpiFectamine Transfection Kit (Life Technologies). Cells were collected at 48 hr after transfection. Although commercially available, MAb cKM4012 (Creative Biolabs Inc) was cloned, expressed and purified in-house to meet reagent quantity requirements ([@bib41]; [@bib39]).

SLC1A5 and SLC1A5_cKM4012 (Fab) complex purification {#s4-2}
----------------------------------------------------

Cells were resuspended at 1:10 (w/v) ratio in 25 mM HEPES pH 7.0, 300 mM NaCl, 0.2 mM Tris (2-carboxyethyl) phosphine (TCEP), buffer supplemented with EDTA free protease inhibitor cocktail (Roche) and 2.5 µl/ml of Benzonase nuclease (Sigma), and disrupted in Microfluidizer processor M110L (Microfluidics) at 12,000 psi. Cell lysate was clarified by centrifugation at 4,000 g for 30 min, and membrane fraction was collected by ultracentrifugation at 225,000 g for 60 min. Membrane pellets were homogenized at 1:5 (w/v) ratio in 25 mM HEPES pH 7.0, 300 mM NaCl, 1% lauryl maltose neopentyl glycol (LMNG) (Anatrace), 0.1% cholesterol hemisuccinate (CHS) (Anatrace), 0.2 mM TCEP buffer followed by 2 hr solubilization with gentle agitation at 4°C. Insoluble material was removed by ultracentrifugation at 290,000 g for 60 min. Solubilized material was incubated overnight at 4°C with anti-flag M2 affinity agarose resin (Sigma) with gentle agitation. 1 ml of the resin efficiently captured solubilized SLC1A5 from 10 g of cells. Unbound material was removed by centrifugation at 1,000 g for 10 min and the resin was washed with 25 mM HEPES pH 7.0, 300 mM NaCl, 0.003% LMNG, 0.2 mM TCEP buffer (buffer A) three times. SLC1A5 was eluted with buffer A supplemented with 0.2 mg/ml Flag peptide (CPC Scientific) and concentrated to 1 mg ml^--\ 1^ using Amicon Ultra Ultracell-100K (Millipore Sigma) centrifugal filter. The affinity purified protein was applied to Superose 6 Increase 10/300 gel filtration column (GE Healthcare) equilibrated with buffer A. All protein purification steps performed on ice or at 4°C at all times.

Fab fragments of cKM4012 monoclonal antibodies were generated using the Fab Preparation Kit (Pierce) and further purified on Superdex 75 column equilibrated with 30 mM HEPES pH 7.0, 100 mM NaCl, 0.003% LMNG, 10 mM L-glutamine (L-Gln). The same buffer without L-Gln was used for samples prepared in the absence of glutamine. When glutamine was present, SLC1A5/cKM4012 (Fab)/L-Gln complex was formed in the followed order: 0.85 ml of SLC1A5 at 16 µM was mixed with 0.05 ml of L-Gln at 200 mM to achieve 10 mM final L-Gln concentration, incubated 20 min in ice, mixed with 1 ml of cKM4012 Fab fragments at 16 µM, incubated 20 min in ice, concentrated to 0.1 ml on Amicon Ultra Ultracell-100K (Millipore Sigma) centrifugal filter. The complex was loaded to Superose 6 10/300 Increase filtration column (GE Healthcare) equilibrated with 25 mM HEPES pH 7.0, 100 mM NaCl, 0.003% LMNG and either 0 mM or 10 mM L-Gln. Two top peak fractions were taken and concentrated to 2 mg/ml.

L-Glutamine uptake assay {#s4-3}
------------------------

HAP1 SLC1A5 knock out (SLC1A5KO) cells (Horizon Discovery HZGHC005452c002) contain a 1 bp insertion in a coding exon of SLC1A5 and do not express SLC1A5 (as described by the vendor and confirmed by us). SLC1A5KO cells were transiently transfected by static electroporation using a MaxCyte STX system. Viable cells (10^6^ per mL) were transfected with 1.0 µg of pcDNA3.1 (empty vector) or with 1 µg of either pcDNA3.1-FL-SLC1A5 or pcDNA3.1-FL-SLC1A5-TEV-His-Flag using the OC-100 or OC-400 processing assembly (electroporation cell) and conditions specified by the vendor. Transfected cells were then cultured at 37°C in a humidified environment in 5% carbon dioxide. After 24 hr, transfected cells were removed flasks and frozen for later use. Glutamine uptake was determined by measuring the incorporation of radio-labeled glutamine into SLC1A5KO cells transfected with the indicated DNA. Specifically, frozen SLC1A5KO cells were thawed then cultured overnight in T-175 flasks in Iscove's modified Dulbecco's medium (Gibco 12440) supplemented with 10% fetal bovine serum. At the time of assay, the cells were removed from flasks with cell dissociation buffer (Gibco 13151), centrifuged at 800 x g, re-suspended in assay buffer (25 mM Tris pH 7.4, 2 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM glucose with or without and 100 mM NaCl) and plated at 50,000 cells per well in a 384-well Cytostar-T scintillation microplate (PerkinElmer RPNQ0166). The plate was then incubated at 37°C in a humidified environment in 5% carbon dioxide. After \~60 min, the plate was removed from the incubator and placed at room temperature (RT). After \~15 min, the assay was initiated by the addition of a mixture of unlabeled glutamine and ^14^C-labeled glutamine (PerkinElmer NEC4150) prepared in assay buffer. The plate was then covered with a plastic seal and \[^14^C\]-glutamine uptake was determined at 40 min by scintillation counting with a MicroBeta2 (2450 Microplate Counter; Perkin Elmer). The final assay volume was 40 µL and the final assay conditions were 25 mM TRIS pH 7.4, 2 mM KCl, 1 mM MgCl~2~, 1 mM CaCl~2~, 5 mM glucose, with or without 100 mM NaCl and 30 µM glutamine/\[^14^C\]-glutamine (50 dpm/pmol).

Grid preparation and data acquisition {#s4-4}
-------------------------------------

3.5 µL of 2.0 mg/ml purified SLC1A5_cKM4012 (Fab) with/without L-Gln complex was applied to the glow-discharged Quantifoil Au R1.2/1.3 grid (Structure Probe), and subsequently vitrified using a Vitrobot Mark IV (FEI Company). In order to overcome an orientation bias, n-octyl-β -d-glucopyranoside (BOG, Anatrace) was added to the sample prior freezing. Cryo grids were loaded into a Titan Krios transmission electron microscope (ThermoFisher Scientific) operating at 300 keV with a Gatan K2 Summit direct electron detector. Images were recorded with SerialEM in super-resolution mode with a super resolution pixel size of 0.543 Å and a defocus range of 1.2 to 2.5 μm. Data were collected with a dose rate of 5 electrons per physical pixel per second, and images were recorded with a 10 s exposure and 250 ms subframes (40 total frames) corresponding to a total dose of 42 electrons per Å^2^. All details corresponding to individual datasets are summarized in [Table 1](#table1){ref-type="table"}.

Electron microscopy data processing {#s4-5}
-----------------------------------

For SLC1A5-cKM4012 (Fab) complex, a total of 3804 dose-fractioned movies were gain-corrected, 2 x binned (resulting in a pixel size of 1.086 Å), and beam-induced motion correction using MotionCor2 ([@bib49]) with the dose-weighting option. The SLC1A5_cKM4012 (Fab) particles were automatically picked from the dose-weighted, motion corrected average images using Gautomatch. CTF parameters were determined by Gctf ([@bib47]). A total of 743,525 particles were then extracted using Relion 2.0 ([@bib36]) with a box size of 224 pixels. The 2D, 3D classification and refinement were performed with Relion 2.0. Two rounds of 2D classification and one round of 3D classification were performed to select the homogenous particles. 3D classification results showed only the outward-facing state with the substrate binding site accessible from the extracellular side. After selecting particle coordinates, per-particle CTF estimation was refined using the program Gctf ([@bib47]). One set of 170,751 particles was then submitted to 3D auto-refinement. All 3D classifications and 3D refinements were started from a 60 Å low-pass filtered version of an ab initio map generated with VIPER ([@bib27]). The particles were re-centered using the refined particle offsets before being re-extracted, followed by parameter conversion and final Auto_Refine in cisTEM ([@bib16]). Auto_Refine in cisTEM, using a soft binary mask that removed the micelle and Fab regions, yielded the final reconstruction at 3.5 Å global resolution, improving the resolution by ∼0.3 Å. The global resolution was evaluated using conventional Fourier Shell Correlation analysis. Prior to visualization, all density maps were sharpened by applying different negative temperature factors (−15,--30, and −50 Å^2^) using automated procedures ([@bib33]), along with the half maps, were used for model building. Local resolution was determined using ResMap ([@bib22]) ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Data collection, processing and refinement of SLC1A5-cKM4012 (Fab) with L-Gln substrate complex were performed similarly as described for SLC1A5-cKM4012 (Fab) ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Fab signals subtraction followed by refinements with/without C3 symmetry operation did not improve the resolutions for both the SLC1A5-cKM4012 (Fab) and SLC1A5-cKM4012 (Fab)\_Gln complexes. The reason could be the Fab-bound SLC1A5 is perhaps pseudo-3 fold symmetric. The presence of the Fab disrupts the low-resolution pseudo-symmetry and facilitates particle alignment. However, the flexibility of the Fabs harms the high-resolution reconstruction at the SLC1A5 trimer regions. A soft binary mask was applied to the SLC1A5 trimer region during the last several rounds of Auto_Refine in cisTEM to improve the local resolution.

Model building and refinement  {#s4-6}
------------------------------

The initial template of the human SLC1A5 was derived from a homology-based model calculated by SWISS-MODEL ([@bib3]). The model was docked into the EM density map using Chimera ([@bib28]) and followed by manually adjustment using COOT ([@bib9]). For the SLC1A5_L-Gln modeling, one L-glutamine molecular was generated and manually docked into the density using COOT. Each model was independently subjected to global refinement and minimization in real space using the module phenix.real_space_refine in PHENIX ([@bib1]) against separate EM half-maps with default parameters. The model was refined into a working half-map, and improvement of the model was monitored using the free half map. The geometry parameters of the final models were validated in Coot and using MolProbity and EMRinger ([@bib4]). These refinements were performed iteratively until no further improvements were observed. The final refinement statistics were provided in [Table 1](#table1){ref-type="table"}. Model overfitting was evaluated through its refinement against one cryo-EM half map. FSC curves were calculated between the resulting model and the working half map as well as between the resulting model and the free half and full maps for cross-validation ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Figures were produced using PyMOL ([@bib37]) and Chimera ([@bib28]).

SLC1A5 proteoliposomes production {#s4-7}
---------------------------------

Liposomes were prepared according to Pingitore et al. with modifications ([@bib29]). A 9:1 mixture of L-α-phosphatidylcholine (PC) (Sigma) and 18:1 biotinyl cap phosphoethanolamine (PE) (Avanti) was dried under N~2~ gas stream, rehydrated in water by vigorous mixing on a vortex mixer followed by extrusion through 400 nm polycarbonate membranes (Sigma) resulting in 6.7% liposomes. SLC1A5 proteoliposomes were formed during detergent-mediated reconstitution. First, pre-made liposomes were mixed with C12E8 to final 1.4% of liposomes and 1.7% of C12E8 in 20 mM Tris, pH 7.0, 10 mM L-Gln followed by 30 min incubation at RT. Second, purified SLC1A5 in 20 mM Tris, pH 7.0, 100 mM 100 NaCl, 10 mM L-Gln, 0.05% n-dodecyl-β-D-maltopyranoside (DDM) and 6 mM β- mercaptoethanol was added to lipid-detergent-micellar solution to make 2000:1 lipid to protein ratio. The protein-lipid-detergent mixture was incubated 30 min at RT before detergents were removed through absorption on hydrophobic resin Amberlite XAD-4. To exchange to an uptake buffer, proteoliposomes were passed through the 7K MWCO Zeba spin desalting columns (ThermoFisher Scientific) equilibrated with 20 mM Tris, pH 7.0, 15 mM Sucrose to balance internal osmolality.

L-glutamine uptake assay using proteoliposomes {#s4-8}
----------------------------------------------

L-glutamine uptake was determined by measuring the incorporation of radio-labeled L-glutamine into biotinylated-SLC1A5 proteoliposomes. Specifically, the assay was initiated by the addition of biotinylated-SLC1A5 proteoliposomes into triplicate wells of a 96-well polypropylene plate with each well containing the indicated concentration of NaCl and 50 *µ*M L-glutamine/L-\[3,4-^3^H)\]-glutamine (100 dpm/pmol). After the indicated time at room temperature (\~22°C), the assay was stopped by the addition of 15 µl of ice-cold streptavidin beads (Pierce Streptavidin Agarose) prepared in 20 mM Tris, pH 7.0, 15 mM sucrose buffer. After 10 min at room temperature the biotin proteoliposome/streptavidin bead complex was transferred to a 96-well GF/C filter plate (PerkinElmer) plate (pre-blocked with 0.1% BSA and washed x 2 in 20 mM Tris, pH 7.0, 15 mM sucrose buffer). The plate was then vacuum filtered and then washed three times with 500 µl per well of ice-cold 20 mM Tris, pH 7.0, 15 mM sucrose buffer. The plate was then air dried overnight and 50 *u*l of Betaplate Scint (PerkinElmer) was added to each well of the 96-well plate. The plate was then sealed and glutamine uptake was determined by scintillation counting with a MicroBeta2 (PerkinElmer).

Cholesteryl hemisuccinate (CHS) detection by untargeted LC/MS {#s4-9}
-------------------------------------------------------------

Purified SLC1A5 protein sample was treated with 10X acetonitrile for 1 hr to denature proteins. Precipitated proteins were pelleted using centrifugation at 15000 x g for 10 min and the supernatant was transferred to a new vial. The supernatant was dried completely using a speed-vac and resuspended with 100 µl of 2:2:1 isopropanol:acetonitrile:water. CHS was detected using high resolution mass spectrometer (Q-Exactive plus) in series with an Agilent 1290 UPLC pump. We modified the waters application note: Lipid Separation using UPLC with Charged Surface Hybrid Technology. Briefly, the mobile phase system consisted of (A) acetonitrile: water (60:40) with 10 mM ammonium formate and 0.1% formic acid and (B) isopropanol:acetonitrile (90:10) with 10 mM ammonium formate and 0.1% formic acid. Metabolites were separated using an Acquity UPLC CSH C18 2.1 × 100 mm, 1.7 µm column heat to 55°C. 10 µL of each sample were subjected to the following gradient: time 0 = 40% B, time 2 = 43% B, time 2.1 = 50% B, time 12 = 54% B, time 12.1 = 70% B, time 18 = 99% B, time 18.1 = 40% B, time 20 = 40% B. The mass spectrometer was set with the following parameters: mass range = 100--1500 m/z, negative mode, 70,000 resolution, AGC target = 1e6, Maximum IT = 100 ms, Centroid, ddMS2 resolution = 30,000, AGC target 1e5, Maximum IT 50 ms, Top N = 5, Loop count = 5, Isolation window = 4.0 m/z, CE = 30. The data were processed using Compound Discoverer 2.0.

We thank James Smith, Chia-Chin Lee, Elizabeth Dushin and Kelsey Oleynek for assisting with cloning, expression and protein purification of SLC1A5. We also thank Mark Tibbitts for cell transfection. We thank Kingsley Sumner for IT support and Ravi Kurumbail for critical reading.
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All the cryo-EM data were deposited to the Protein Data Bank (PDB ID: 6MP6, 6MPB) and the EMDB (EMD-9187, EMD-9188) for immediate release upon publication.

The following datasets were generated:

YuXPlotnikovaOBoninPDSubashiTAMcLellanTJDumlaoDCheYDongYYCarpenterEPWestGMQiuXCulpJSHanS2019SLC1A5_cKM4012Protein Data Bank6MP6

YuXPlotnikovaOBoninPDSubashiTAMcLellanTJDumlaoDCheYDongYYCarpenterEPWestGMQiuXCulpJSHanS2019SLC1A5_cKM4012_L\_GlnProtein Data Bank6MPB

YuXPlotnikovaOBoninPDSubashiTAMcLellanTJDumlaoDCheYDongYYCarpenterEPWestGMQiuXCulpJSHanS2019SLC1A5_cKM4012Electron Microscopy Data BankEMD-9187

YuXPlotnikovaOBoninPDSubashiTAMcLellanTJDumlaoDCheYDongYYCarpenterEPWestGMQiuXCulpJSHanS2019SLC1A5_cKM4012_L\_GlnElectron Microscopy Data BankEMD-9188
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Structural basis for the transport mechanism of the human glutamine transporter SLC1A5 (ASCT2)\" for consideration by *eLife*. Your article has been reviewed by Olga Boudker as the Senior Editor, a Reviewing Editor and three peer reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Robert John Vandenberg (Reviewer \#3); Joel Meyerson (Reviewer \#4).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The neutral amino acid transporter ASCT2 is a member of the SLC1 family of transporters and a target of cancer therapeutics. The manuscript by Yu et al. presents the determination of a structure of ASCT2 in an outward-facing conformation, complementing a previously published structure of an inward facing structure of ASCT2, and providing details of the substrate binding site, which should prove invaluable for the design of drugs to inhibit the transporter.

The reviewers appreciate the high quality of the structural work and general importance of the structure, but note that it requires a more direct connection to physiology, e.g. the differences between exchangers and transporters, and/or to drug design. To focus the framing of the article we therefore strongly suggest that you rewrite the article as a Short Report, focus on the substrate and putative CHS binding sites, and exclude the HDX data as explained below.

Essential revisions:

The following are the points that should be considered when improving the physiological context of the structure in the revised manuscript:

1\) Based on the structures, is it clear why ASCT2 and ASCT1 have different substrate specificity?

2\) From the drug design perspective please provide more specific comments on the potential applications of the structure for the development of drugs.

3\) It is not clear whether the protein imaged without L-Gln was in high Na^+^ concentration. If yes, then the structure likely represents a Na^+^-bound transporter, which should be evident from the arrangement of the Na^+^-binding residues. If not, or if the affinity for Na^+^ is low, then one would expect to find disrupted Na^+^ binding sites, which again should be visible in the structure.

4\) ASCTs are obligate Na^+^-dependent exchangers, while EAATs are concentrative pumps. Could it be rationalized from the structures, why ASCT2 cannot return to the outward-facing states without the bound amino acid and Na^+^ ions?

5\) Mutations have been made in GltPh mimicking ASCT2 (including R to C mutation), but when the structure was solved with Gln, the HP2 loop was still open. Can it be rationalized from the current structure what is the difference between the binding pockets and/or HP2 between ACST2 and GltPh that allows larger substrates (even when R is mutated to C)?

6\) The manuscript methodically indexes many structural features including protomer interactions, helix orientations, key amino acid positions, glycosylation sites, glutamine and CHS binding sites, etc. However, this style is primarily descriptive, so if the authors intend to retain these details, they should to be enhanced with a clearer narrative explaining the significance of the structural findings. Below are three examples.

The authors point out that \"based on sequence alignment, both SLC1A4 and SLC1A5 have the longest ECL2a region compared to other SLC1 family members including prokaryotic homologues.\" What is the significance of this?

Similarly, the authors write: \"Importantly, the ECL2b was reported to play a critical role in determining the receptor properties of SLC1A5 for retroviruses.\" Can the structure help rationalize this previous report?

The authors write: \"Similarly, Arg376 of the transport domain has a potential to form a salt bridge with the Glu264 of scaffold domain in the outward-facing structure (Figure 3B-C). Both Arg376 and Glu264 are highly conserved among the SLC1 family (Figure 1---figure supplement 6).\" What are the implications of these observations?

In addition, please address the following issues in the manuscript and/or in responses to the reviewers:

1\) Is it known if the Fabs used to aid particle alignment influence transport?

2\) The characterization of the transport properties of ASCT2 are based on a single concentration of substrate, which generates a signal to noise ratio of 2. This level of analysis does not instill sufficient confidence in the functional properties of the transporter. It would be preferable to have a measure of substrate affinity, and also demonstration of the exchange properties of the transporter, which would reflect previous studies measuring the functional properties of ASCT2.

3\) How significant are the deviations form 3-fold symmetry between protomers? From the superpositions it looks like the deviations are truly minute. Is higher resolution obtained if 3C symmetry is imposed during 3D alignment and refinement? If yes, improved resolution may help analyzing the status of Na^+^ binding sites.

4\) Have the authors attempted to perform symmetry expansion to detect whether there is any heterogeneity in the protomers? Such heterogeneity might be masked even if C1 is used for processing.

5\) The HDX-MS data is analyzed only very superficially, and as it stands, the level of detail provided does not allow a thorough analysis of the data. On the face of it, these data also do not appear to add significant understanding to the physiological mechanism nor the drug targeting of ASCT2. We recommend removing this section and publishing elsewhere.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Olga Boudker as the Senior Editor, and a Reviewing Editor.

The manuscript has been improved but there is one remaining issue that needs to be addressed before acceptance, as outlined below:

\- Since it appears that little uptake activity is seen (over the background) in either cells or proteoliposomes, please move Figure 1A to the supplementary information and state in the main text explicitly that the observed transport activity was low, compared to the background. Please also use color to distinguish the points in that figure.

10.7554/eLife.48120.027

Author response

> Summary:
>
> The neutral amino acid transporter ASCT2 is a member of the SLC1 family of transporters and a target of cancer therapeutics. The manuscript by Yu et al. presents the determination of a structure of ASCT2 in an outward-facing conformation, complementing a previously published structure of an inward facing structure of ASCT2, and providing details of the substrate binding site, which should prove invaluable for the design of drugs to inhibit the transporter.
>
> The reviewers appreciate the high quality of the structural work and general importance of the structure, but note that it requires a more direct connection to physiology, e.g. the differences between exchangers and transporters, and/or to drug design. To focus the framing of the article we therefore strongly suggest that you rewrite the article as a Short Report, focus on the substrate and putative CHS binding sites, and exclude the HDX data as explained below.

We would like to thank the reviewers for their valuable time and careful and critical evaluation of our manuscript. We have addressed each of their concerns to the best of our ability as described below. We have rewritten the article as a more concise Short Report that focuses on the substrate and CHS binding sites and we have removed the HDX data as requested by the editor.

> Essential revisions:
>
> The following are the points that should be considered when improving the physiological context of the structure in the revised manuscript:
>
> 1\) Based on the structures, is it clear why ASCT2 and ASCT1 have different substrate specificity?

Careful comparison of the sequences of ASCT1 and ASCT2 around the substrate binding site show that the most significant difference is at position 467 -- ASCT1 has a threonine at this position while ASCT2 has a cysteine. The side chain sulfhydryl group of Cys 467 in ASCT2 appears to form a hydrogen bond with the side chain of glutamine in our structure. Since the structure of ASCT1 is unknown, we attempted to generate a model for ASCT1 by replacing Cys with a threonine. Unfortunately, none of the three rotamers available for threonine can be satisfactorily accommodated because of steric clashes with backbone carbonyl atoms. This suggests that ASCT1 must have a slightly different local conformation around the substrate binding site. Regardless of the local conformation that ASCT1 adopts in this region, the side chain hydroxyl group of Thr459 (analogous to Cys467 in ASCT2) is unlikely to form a productive hydrogen bonding interaction with the glutamine substrate and this could explain why the former transports only fewer amino acids. We have incorporated this description into our revised manuscript.

> 2\) From the drug design perspective please provide more specific comments on the potential applications of the structure for the development of drugs.

SLC1A5 is a high value target in the pharmaceutical industry for the development of drugs for immunomodulatory drugs. The availability of the three-dimensional structure of SLC1A5 in its outward facing conformation open several paths forward for the development of drugs. (1) The structure could be used for identification of chemical leads by virtual screening methods. (2) Secondly, generating additional structures with lead molecules based on substrate-analogs could provide a strong structure-based drug design platform for medicinal chemistry optimization of compound potencies. (3) One important aspect of drug discovery is the need to engineer selectivity of lead compounds for the specific target in a given subfamily. This is especially true for modulators of SLC1A5 where dialing out off-target activities against other closely-related sub-family members is highly desirable. Historically, this has been an area of strength for structure-based design. (4) Structures have also been incredibly useful for optimization of ADME properties of compounds which is a critical element in the overall drug discovery process. (5) We believe the most relevant conformation to target for SLC1A5 inhibitors is the outward-facing conformation that we have described in our current work as that is the most relevant conformation for ligands from extracellular space. We have revised the manuscript to incorporate the above section.

> 3\) It is not clear whether the protein imaged without L-Gln was in high Na^+^ concentration. If yes, then the structure likely represents a Na^+^-bound transporter, which should be evident from the arrangement of the Na^+^-binding residues. If not, or if the affinity for Na^+^ is low, then one would expect to find disrupted Na^+^ binding sites, which again should be visible in the structure.

We agree this is an important question to address. All protein samples in this work were imaged in presence of 100 mM NaCl. Thus, we do believe our apo structure represents Na-bound state of the transporter. We have revised the Materials and methods section to clearly state this. Given the moderate resolution of the structure and the lack of density for sodium and nearby side chains, we are unable to make a categorical statement regarding this. Future structures of ASCTs at different sodium concentrations and at higher resolution could help to clarify the precise role sodium plays in conformational switching.

> 4\) ASCTs are obligate Na^+^-dependent exchangers, while EAATs are concentrative pumps. Could it be rationalized from the structures, why ASCT2 cannot return to the outward-facing states without the bound amino acid and Na^+^ ions?

This is also a very interesting question, but difficult to assess due to the fact that sodium ion is not visible in our structure and we do not have a structure in its absence. It is highly likely that significant conformational changes accompanies binding of sodium ions. Based on our structures in the presence and absence of glutamine, we do know that the presence of substrate does not impede the movement of HP2 loop. It is possible that higher resolution structures with and without both Na^+^ and Gln bound may shed light on this mechanism.

> 5\) Mutations have been made in GltPh mimicking ASCT2 (including R to C mutation), but when the structure was solved with Gln, the HP2 loop was still open. Can it be rationalized from the current structure what is the difference between the binding pockets and/or HP2 between ACST2 and GltPh that allows larger substrates (even when R is mutated to C)?

We believe the editor is referring to the work of Scopelliti et al., 2018, which describes the structures of GltPH (R397C) bound to serine, cysteine or benzylCys. However, there is no Gln-bound structure of GltPh (WT or R397C mutant) that has been reported. In the Cys-bound GltPh-R397C structure, the HP2 loop adopts a "closed" conformation. Similarly, the HP2 loop is closed in one of the protomers in the Ser-bound GltPh structure, However, electron density suggests open conformations for the other two protomers but they were not modeled due to limited resolution. Therefore, it would be difficult to assess/compare structures of ASCT2 and GltPh with bound glutamine or comment on the precise conformation of the HP2 loop.

> 6\) The manuscript methodically indexes many structural features including protomer interactions, helix orientations, key amino acid positions, glycosylation sites, glutamine and CHS binding sites, etc. However, this style is primarily descriptive, so if the authors intend to retain these details, they should to be enhanced with a clearer narrative explaining the significance of the structural findings. Below are three examples.

We thank reviewers for pointing out the description of structural features. Some of them have been streamlined or removed to fit the "short report" style and focus on the significance of the structural findings.

> The authors point out that \"based on sequence alignment, both SLC1A4 and SLC1A5 have the longest ECL2a region compared to other SLC1 family members including prokaryotic homologues.\" What is the significance of this?

As there is no significance, we have removed the sentence.

> Similarly, the authors write: \"Importantly, the ECL2b was reported to play a critical role in determining the receptor properties of SLC1A5 for retroviruses.\" Can the structure help rationalize this previous report?

As the structure doesn't rationalize, we have removed.

> The authors write: \"Similarly, Arg376 of the transport domain has a potential to form a salt bridge with the Glu264 of scaffold domain in the outward-facing structure (Figure 3B-C). Both Arg376 and Glu264 are highly conserved among the SLC1 family (Figure 1---figure supplement 6).\" What are the implications of these observations?

In the revised "Short Report" version, we removed the discussion.

> In addition, please address the following issues in the manuscript and/or in responses to the reviewers:
>
> 1\) Is it known if the Fabs used to aid particle alignment influence transport?

The biochemical role of the KM4012 for transport activity is currently unknown. It is reported that KM4012 antibody was isolated through a cell-based screen and inhibited glutamine-dependent cancer cell growth (Suzuki et al). The antibodies suppressed glutamine-dependent growth of WiDr colorectal cancer cells, which require glutamine in the culture medium to grow.

In this revised version we added a sentence "It is reported that KM4012 antibody isolated through a cell based screen inhibited glutamine-dependent cancer cell growth. (Suzuki et al)" for further clarification.

> 2\) The characterization of the transport properties of ASCT2 are based on a single concentration of substrate, which generates a signal to noise ratio of 2. This level of analysis does not instill sufficient confidence in the functional properties of the transporter. It would be preferable to have a measure of substrate affinity, and also demonstration of the exchange properties of the transporter, which would reflect previous studies measuring the functional properties of ASCT2.

Thank you for pointing out the weak signal to noise ratio. The level of glutamine transport measured with our SLC1A5 PL assay system was \~6 times lower than the level reported by Pingatore et al. and by Graraeva et al. While Pingatore et al. reported that SLC1A5 in their proteoliposomes (PL) was 100% in the correct orientation (i.e. an orientation needed to measure glutamine uptake PL) only 20-25% of the SLC1A5 in our PL was in that same correct orientation (determined by the availability of an affinity tag in relation to PL surface (data not shown). This could be due to differences in the expression systems that were used by the two different labs. Both Pingatore et al. and Graraeva et al. used a yeast expression system, but our expression system used the mammalian HEK293 cell line. These differences could account for weaker signal we observed in our assay.

In lieu of further PL experiments, we demonstrate that when expressed in cells, the affinity-tagged SLC1A5 used in this study produced a level of glutamine uptake that was comparable to untagged WT SLC1A5, thus suggesting that the presence of the affinity-tags did not alter the biological activity of SLC1A5. To make it more evident that the glutamine transport activity of our tag-version of SLC1A5 is comparable to the wild type protein, we tested a broad range of glutamine concentration and both wild type and the tag version of SLC1A5 showed similar activity. This is depicted in the revised Figure 1A.

We have also explored biophysical studies using SPR but were unsuccessful due to technical challenges with the detergent solubilized protein reagent.

> 3\) How significant are the deviations form 3-fold symmetry between protomers? From the superpositions it looks like the deviations are truly minute. Is higher resolution obtained if 3C symmetry is imposed during 3D alignment and refinement? If yes, improved resolution may help analyzing the status of Na^+^ binding sites.

From the Supplementary Figure 7 (initial submission) on the superposition of each protomer, the results revealed that three protomers from the outward-facing SLC1A5 trimers share similar global fold but are not positioned symmetrically in space. Even though the deviations are truly minute, the fab-bound SLC1A5 trimers adopt the pseudo C3 symmetry and imposing C3 operation during the refinement did not improve the resolution further. The reason could be the presence of the Fab disrupts the low-resolution pseudosymmetry. We further experimented with Fab signals subtraction followed by refinements with/without C3 symmetry operation and the efforts did not improve. the resolution for the SLC1A5-cKM4012 (Fab) structure or the SLC1A5-cKM4012 (Fab)\_Gln complex. In the revised "Short Report" version, we removed this figure.

> 4\) Have the authors attempted to perform symmetry expansion to detect whether there is any heterogeneity in the protomers? Such heterogeneity might be masked even if C1 is used for processing.

Since the structures were reconstructed without any symmetry operations, no symmetry expansion was performed. From the 3D classification and the final reconstruction results, only the outward-facing state was observed. Minor heterogeneities were observed at the loop regions among the protomers.

> 5\) The HDX-MS data is analyzed only very superficially, and as it stands, the level of detail provided does not allow a thorough analysis of the data. On the face of it, these data also do not appear to add significant understanding to the physiological mechanism nor the drug targeting of ASCT2. We recommend removing this section and publishing elsewhere.

We have removed the HDX section.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there is one remaining issue that needs to be addressed before acceptance, as outlined below:
>
> \- Since it appears that little uptake activity is seen (over the background) in either cells or proteoliposomes, please move Figure 1A to the supplementary information and state in the main text explicitly that the observed transport activity was low, compared to the background. Please also use color to distinguish the points in that figure.

We appreciate the referee's concern and comment. We have moved "Figure 1A" to "Figure 1---figure supplement 1A". The figure was revised in color to distinguish the points. We have also explicitly stated in the main text to read "Our full-length SLC1A5 construct showed high expression and stability. (Figure 1---figure supplement 1). The presence of affinity tags used for purification did not affect the sodium-dependent glutamine uptake when HAP1 SLC1A5 knock-out cells were transiently transfected with full-length SLC1A5 but the observed transport activity was low, compared to the background." in the revised manuscript.
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